Imatinib Zentiva

Imatinib, the active ingredient in Imatinib Zentiva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of certain blood cancers and gastrointestinal stromal tumors in adult patients. By blocking specific cellular enzymes, it helps to control abnormal cell growth.

GNH USA supplies Imatinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑compliant documentation to support import and clinical use.

Imatinib targets abnormal tyrosine kinase signaling in certain hematologic and solid tumors. - Chronic myeloid leukemia (CML): achieves durable molecular remission and disease control. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control and improves survival outcomes. - Gastrointestinal stromal tumor (GIST): reduces tumor progression and can induce tumor shrinkage.

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet or face. - Muscle cramps: intermittent tightness or pain in muscles. - Fatigue: persistent tiredness. - Diarrhea: loose stools occurring intermittently. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia: significant reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function. - Severe hemorrhage: unexpected bleeding. - Pulmonary hypertension: increased pressure in lung arteries. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

Patients should be monitored closely for safety concerns and appropriate laboratory assessments. - Monitor blood counts: perform regular complete blood count tests. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: conduct baseline and periodic cardiac assessments. - Avoid strong CYP3A4 inhibitors: these may increase drug exposure. - Counsel on pregnancy risks: discuss potential fetal effects with women of childbearing potential. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma levels and increase toxicity. - Concurrent use with other tyrosine kinase inhibitors: may lead to additive adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug concentrations and reduce efficacy. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): can increase risk of fluid retention and edema.